Share This Article:

Preliminary Colorimetric Assessment of Progressive Nonsegmental Vitiligo under Short-Term Intravenous Methylprednisolone Pulse Therapy

Abstract Full-Text HTML Download Download as PDF (Size:356KB) PP. 135-140
DOI: 10.4236/jcdsa.2014.43019    3,457 Downloads   4,427 Views   Citations

ABSTRACT

Although the administration of systemic steroid for nonsegmental vitiligo in the progressive stage is a recommended treatment according to guidelines, the clinical efficacy of this regimen has not been fully established. In this study, we evaluated the clinical efficacy of half-dose steroid treatment and stratified the evidence regarding its usefulness in progressive vitiligo patients. Half-dose steroid pulse therapy (500 mg/day of methylprednisolone for three sequential days) was administered intravenously three times monthly in five vitiligo patients. The visual changes in vitiligo lesions were evaluated on photographs and quantified using a spectrophotometer. As results, all patients completed three cycles of treatment without severe adverse events. Three of the five patients achieved disease arrest with decrease in white contrast. Therefore, short-term and halfdose steroid therapy is well tolerated and effective for achieving disease arrest in progressive nonsegmental vitiligo. The whiteness assessed by a spectrophotometer is possibly associated with therapeutic response to steroid therapy.

Cite this paper

Nagata, Y. , Tanemura, A. , Ono, E. , Tanaka, A. , Kato, K. , Yamada, M. and Katayama, I. (2014) Preliminary Colorimetric Assessment of Progressive Nonsegmental Vitiligo under Short-Term Intravenous Methylprednisolone Pulse Therapy. Journal of Cosmetics, Dermatological Sciences and Applications, 4, 135-140. doi: 10.4236/jcdsa.2014.43019.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Taieb, A., Alomar, A., Bohm, M., Dell’Anna, M.L., De Pase, A., Elefttheriadou, V., Ezzedine, K., Gauthier, Y., Gawkrodger, D.J., Jouary, T., Leone, G., Moretti, S., Nieuweboer-Krobotova, L., Olsson, M.J., Parsad, D., Passeron, T., Tanew, A., van der Veen, W., van Geel, N., Whitton, M., Wolkerstorfer, A. and Picardo, M. (2013) Guidelines for the Management of Vitiligo: The European Dermatology Forum Consensus. British Journal of Dermatology, 168, 5-19. http://dx.doi.org/10.1111/j.1365-2133.2012.11197.x
[2] Oiso, N., Suzuki, T., Wataya-Kaneda, M., Tanemura, A., Tanioka, M., Fujimoto, T., Fukai, K., Kawakami, T., Tsukamoto, K., Yamaguchi, Y., Sano, S., Mitsuhashi, Y., Nishigori, C., Morita, A., Nakagawa, H., Mizoguchi, M. and Katayama, I. (2013) Guidelines for the Diagnosis and Treatment of Vitiligo in Japan. Journal of Dermatology, 40, 1-11. http://dx.doi.org/10.1111/1346-8138.12099
[3] Radakovic-Fijan, S., Fürnsinn-Friedl, A.M., Honigsmann, H. and Tanew, A. (2001) Oral Dexamethasone Pulse Treatment for Vitiligo. Journal of American Academy of Dermatology, 44, 814-817.
http://dx.doi.org/10.1067/mjd.2001.113475
[4] Kim, S.M., Lee, H.S. and Hann, S.K. (1999) The Efficacy of Low-Dose Oral Corticosteroids in the Treatment of Vitiligo Patients. International Journal of Dermatology, 38, 546-550.
http://dx.doi.org/10.1046/j.1365-4362.1999.00623.x
[5] Pasricha, J.S. and Khaitan, B.K. (1993) Oral Mini-Pulse Therapy with Betamethasone in Vitiligo Patients Having Extensive or Fast-Spreading Disease. International Journal of Dermatology, 32, 753-757.
http://dx.doi.org/10.1111/j.1365-4362.1993.tb02754.x
[6] Seiter, S., Ugurel, S., Tilgen, W. and Reinhold, U. (2000) Use of High-Dose Methylprednisolone Pulse Therapy in Patients with Progressive and Stable Vitiligo. International Journal of Dermatology, 39, 624-627. http://dx.doi.org/10.1046/j.1365-4362.2000.00006.x
[7] Hertz, K.C., Gazze, L.A., Kirkpatrick, C.H. and Katz, S.I. (1977) Autoimmune Vitiligo: Detection of Antibodies to Melanin-Producing Cells. New England Journal of Medicine, 297, 634-637.
http://dx.doi.org/10.1056/NEJM197709222971204
[8] Barret, D.F. and Lee, H.A. (1982) Corticosteroid Pulse Therapy in Dermatology. British Journal of Dermatology, 107, 31.
[9] Lee, Y., Seo, Y.J., Lee, J.H. and Park, J.K. (2007) High-Dose Prednisolone and Psoralen Ultraviolet A Combination Therapy in 36 Patients with Vitiligo. Clinical and Experimental Dermatology, 32, 499-501. http://dx.doi.org/10.1111/j.1365-2230.2007.02387.x
[10] Tanemura, A., Takahashi, A., Ueki, Y., Murota, H., Yamaguchi, Y. and Katayama, I. (2012) Therapeutic Comparison between Sun Irradiation vs. Narrowband UVB Phototherapy along with Topical Tacalcitol for Vitiligo Vulgaris. Journal of Cosmetics, Dermatological Sciences and Applications, 2, 88-91. http://dx.doi.org/10.4236/jcdsa.2012.22020
[11] Jian, D., Jiang, D., Su, J., Chen, W., Hu, X., Kuang, Y., Xie, H., Li, J. and Chen, X. (2011) Diethylstilbestrol Enhances Melanogenesis via cAMP-PKA-Mediating Up-Regulation of Tyrosinase and MITF in Mouse B16 Melanoma Cells. Steroids, 76, 1297-1304.
http://dx.doi.org/10.1016/j.steroids.2011.06.008
[12] Birlea, S.A., Costin, G.E. and Norris, D.A. (2009) New Insights on Therapy with Vitamin D Analogs Targeting the Intracellular Pathways That Control Repigmentation in Human Vitiligo. Medicinal Research Reviews, 29, 514-546. http://dx.doi.org/10.1002/med.20146

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.